LACTOLOGY FOUNDATION

Cerebrovascular Disorders: An Academic Review of Pathophysiology, Diagnosis, Acute Management, and Secondary Prevention

Primary Classification and Etiologic Subtypes

Cerebrovascular disease encompasses a spectrum of acute neurological conditions caused by disrupted cerebral blood flow. Stroke is clinically defined as an abrupt focal neurological deficit resulting from either focal brain ischemia or intracranial hemorrhage. Ischemic stroke accounts for approximately 80% of all cerebrovascular events, whereas hemorrhagic stroke comprises the remaining 20%. Hemorrhagic strokes are further categorized into intracerebral hemorrhage (ICH), which accounts for 15% of strokes, and subarachnoid hemorrhage (SAH), which represents approximately 5%.

A transient ischemic attack (TIA) is defined as a temporary, vascular-induced focal neurological deficit that resolves completely. Classically defined by a symptom duration of less than 24 hours—and typically lasting under one hour—a TIA is not a benign transient phenomenon, but rather a warning signal that heralds impending full-thickness cerebral infarction and offers an essential window for immediate preventive intervention.

Ischemic stroke pathogenesis is divided into three primary categories accounting for 70% to 90% of cases: cardioembolism, large-vessel atherothromboembolism, and small-vessel occlusive disease (lacunar infarction). The remaining proportion arises from uncommon specified etiologies—such as cervicocephalic arterial dissection, central nervous system vasculitis, and hypercoagulable states—or is classified as cryptogenic (idiopathic) when exhaustive clinical evaluation fails to identify a definitive source.

Epidemiology and Demographic Disparities

Stroke remains a leading cause of long-term adult disability and a major contributor to mortality globally. Population-based surveillance datasets, such as the Greater Cincinnati/Northern Kentucky Stroke Study, demonstrate an estimated annual incidence of over 731,100 stroke events in the United States. Epidemiological analyses reveal significant demographic and racial disparities in stroke incidence, mortality, and underlying vascular mechanisms.

African American populations experience a two- to four-fold higher incidence of stroke compared to non-Hispanic white populations. Mortality figures reflect a similar excess burden; African American males aged 45 to 59 exhibit a 306% higher stroke-related mortality rate relative to non-Hispanic whites of the same age cohort. While extracranial carotid atherosclerosis and cardioembolism predominate as the primary mechanisms of ischemic stroke in non-Hispanic whites, intracranial thromboembolic disease occurs with significantly higher frequency in African American and Hispanic populations.

Sex-specific epidemiological patterns indicate that males exhibit higher age-adjusted stroke rates across younger and middle-aged demographics. However, among individuals aged 75 years and older—where absolute stroke incidence reaches its zenith—women experience higher overall stroke rates. In specific regional cohorts, up to 61% of total stroke-related deaths occur in female patients, underscoring the critical necessity of aggressive targeted secondary prevention across aging female populations.

Pathophysiology and Ischemic Cascade Dynamics

The central pathophysiological event in acute ischemic stroke is the sudden disruption of regional cerebral blood flow ($CBF$), depriving neural tissue of vital oxygen and glucose substrates. When regional perfusion drops below critical threshold levels, cellular energy failure ensues. Depletion of adenosine triphosphate (ATP) halts $Na^+/K^+$-ATPase transmembrane pumps, causing neuronal membrane depolarization, unchecked intracellular calcium ($Ca^{2+}$) influx, massive release of excitotoxic glutamate into the extracellular space, and activation of catabolic enzymes that trigger acute necrotic cell death within the core of the infarct.

Surrounding the central, irreversibly damaged necrotic core lies the ischemic penumbra. The penumbra represents dynamic, hypoperfused neural tissue where metabolic integrity is minimally maintained but electrical activity is silent. Unassisted, penumbral tissue undergoes progressive cellular recruitment into the expanding necrotic core over hours via delayed apoptotic cascades, peri-infarct depolarizations, microvascular oxidative stress, and inflammatory tissue degradation. Modern neuroimaging techniques operationalize this phenomenon through diffusion-perfusion mismatch paradigms. Diffusion-weighted magnetic resonance imaging (DWI) identifies cytotoxic edema corresponding to the established core, whereas perfusion-weighted imaging (PWI) defines the entire realm of reduced blood supply. The volumetric difference between PWI and DWI defects quantifies the salvageable ischemic penumbra, which represents the primary therapeutic target of hyperacute revascularization interventions.

Pathophysiological mechanisms vary across specific ischemic categories:

• Cardioembolism: Intracardiac stasis or altered endothelial integrity leads to intra-atrial or intra-ventricular thrombus formation. Dislodged cardiac emboli characteristically travel to major intracranial branch points, frequently causing sudden, severe occlusions with high initial neurological deficits across multiple vascular territories.
• Large-Vessel Atherothromboembolism: Chronic lipid accumulation, smooth muscle cell proliferation, and local inflammation form arterial wall plaques at high-shear stress sites, such as the carotid bifurcation or subclavian-vertebral junctions. Plaque rupture or erosion exposes subendothelial collagen, provoking immediate platelet aggregation and fibrin-clot formation, which either occludes the lumen directly or embolizes distally.
• Small-Vessel Occlusive Disease: Chronic, unmanaged systemic hypertension and diabetes induce lipohyalinosis, microatheroma formation, and microthrombosis within small penetrating end-arteries supplying the deep basal ganglia, internal capsule, thalamus, and pons. Occlusion yields small, discrete subcortical cavitary lesions termed lacunar infarctions.

In hemorrhagic stroke, pathophysiological destruction is mediated by direct extravasation of blood under pressure. In ICH, chronic arterial hypertension leads to the development of microaneurysms in deep penetrating vessels that eventually rupture. Mass effect, direct tissue tearing, rapid hematoma expansion in the first 24 hours, and subsequent peri-hematomal edema induce profound elevation in intracranial pressure ($ICP$), secondary toxic ischemia, and herniation risk. In aneurysmal SAH, arterial wall weakness at Circle of Willis bifurcations leads to saccular outpouchings that rupture directly into the subarachnoid space, inducing immediate spikes in $ICP$, severe chemical meningismus, secondary arterial vasospasm, and communicating hydrocephalus.

Clinical Manifestations and Neuro-Localization

The clinical presentation of acute ischemic stroke depends directly on the specific neurovascular territory rendered ischemic. The brain is supplied by two pairs of major arteries: the internal carotid arteries (anterior circulation) and the vertebral arteries (posterior circulation), which coalesce along the ventral brainstem to form the basilar artery and the Circle of Willis.

Anterior circulation syndromes encompass the territories of the anterior cerebral artery (ACA) and middle cerebral artery (MCA). ACA occlusion primarily affects the medial frontal and parietal cortices, manifesting clinically as contralateral lower-extremity motor weakness and sensory loss exceeding upper-extremity involvement, accompanied by abulia and gait apraxia. The MCA supplies the expansive lateral cortical surfaces of the frontal, parietal, and temporal lobes, along with deep subcortical structures via lenticulostriate perforators. Complete MCA occlusion yields a classic, profound neuro-deficit syndrome consisting of contralateral hemiparesis and hemisensory loss (predominantly involving the face and upper extremity relative to the leg), contralateral homonymous hemianopia, gaze preference directed toward the side of the cerebral lesion, and dysarthria. Cortical signs are pivotal for hemispheric lateralization: dominant hemispheric MCA lesions yield expressive, receptive, or global aphasia; non-dominant hemispheric MCA lesions result in hemispatial neglect, anosognosia, and spatial dyspraxia.

Posterior circulation syndromes involve the posterior cerebral arteries (PCA), vertebral arteries, basilar artery, and cerebellar arterial branches. PCA occlusion isolates the occipital lobe and medial temporal structures, producing contralateral homonymous hemianopia with macular sparing, sensory loss, visual agnosia, and variable hemiparesis. Vertebrobasilar occlusive disease induces brainstem and cerebellar ischemia, presenting with characteristic "crossed" neuro-deficits—defined as ipsilateral cranial nerve palsies coupled with contralateral body motor hemiparesis or sensory loss. Key posterior circulation signs include ataxia, vertigo, diplopia, dysarthria, dysphagia, nystagmus, nausea, vomiting, tinnitus, hearing loss, and sudden fluctuations in consciousness. Basilar artery trunk occlusion can precipitate catastrophic brainstem infarction resulting in quadriplegia, bulbar paralysis, and locked-in syndrome.

Lacunar syndromes result from small-vessel penetrating artery occlusions and are clinically distinguished by the absence of cortical signs (such as aphasia, apraxia, neglect, or visual field deficits). Classic lacunar syndromes include pure motor hemiparesis, pure sensory stroke, clumsy hand-dysarthria syndrome, and ataxic hemiparesis.

Diagnostic Protocols and Neuroimaging

Rapid triage and urgent neuroimaging form the cornerstone of acute stroke evaluation. The clinical diagnostic pathway requires rapid assessment of airway, breathing, and circulation (ABCs), point-of-care finger-stick blood glucose measurement to immediately rule out severe hypoglycemia, and execution of a validated clinical stroke scale, primarily the National Institutes of Health Stroke Scale (NIHSS).

Emergency neuroimaging must be performed immediately upon patient presentation to definitively differentiate ischemic stroke from acute intracranial hemorrhage. Non-contrast computed tomography (NCCT) of the head remains the initial imaging modality of choice due to its high availability and sensitivity for detecting hyperacute extravascular blood. While NCCT exhibits lower sensitivity for subtle ischemic tissue changes within the first few hours post-onset, early ischemic signs can be detected. These subtle early signs include hyperdense vessel signs (suggestive of acute intraluminal thrombus), loss of gray-white matter boundaries (such as obscuration of the lentiform nucleus or insular ribbon), and sulcal effacement.

When hyperacute parenchymal hemorrhage is ruled out on NCCT, advanced neuroimaging modalities provide detailed structural, metabolic, and vascular information. Magnetic resonance imaging (MRI) utilizing diffusion-weighted imaging (DWI) demonstrates hyperacute ischemic lesions within minutes of symptom onset, displaying high hyperintensity indicative of cytotoxic edema. Perfusion-weighted imaging (PWI) maps cerebral blood flow. Demonstrating a structural mismatch between a larger PWI perfusion defect and a smaller DWI diffusion core confirms the presence of salvageable ischemic penumbra. Non-invasive vascular imaging—specifically CT angiography (CTA) or magnetic resonance angiography (MRA)—rapidly identifies large-vessel intracranial occlusions, luminal stenosis, or cervical arterial dissections. Transcranial Doppler (TCD) ultrasonography provides non-invasive bedside evaluation of major vessel occlusion and real-time monitoring of recanalization during thrombolytic infusion. Digital subtraction angiography (DSA) remains the gold standard for vascular resolution, reserved for complex cases or planned endovascular interventions.

Comprehensive etiologic evaluation requires systematic cardiac, vascular, and laboratory testing. Cardiac evaluation includes continuous ECG monitoring, history taking, and either transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE). If TTE is inconclusive but high clinical suspicion for a cardioembolic source persists (e.g., mural thrombus, valvular disease, or patent foramen ovale), TEE is ordered to visualize structures not seen on TTE, including left atrial appendage clots and aortic arch atheromas. Laboratory testing protocol encompasses fasting blood lipid profiles, complete blood count with platelets, prothrombin time (PT), partial thromboplastin time (PTT), chemistry panels, and serum homocysteine. In younger stroke patients ($<45 \text{ years}$) or those lacking conventional cardiovascular risk factors, an expanded hypercoagulability panel is indicated, including tests for anticardiolipin antibodies, lupus anticoagulant profile, erythrocyte sedimentation rate (ESR), Factor V Leiden, Protein C, Protein S, antithrombin III, rapid plasmin reagin (RPR), antinuclear antibodies (ANA), and prothrombin gene mutations.

Differential Diagnosis Matrix

Systematic differential diagnosis is essential, as numerous non-vascular systemic, metabolic, and central nervous system disorders can mimic acute stroke presentations.

Metabolic derangements, particularly hypoglycemia and hyperglycemia, are notorious stroke mimics that can generate focal neurological signs. Point-of-care capillary blood glucose screening must be performed immediately upon patient arrival. Postictal Todd’s paresis following an unobserved seizure frequently presents with focal weakness, requiring careful clinical history taking. Complicated migraines presenting with prolonged aura can mimic cerebral ischemia; headache can be a prominent component of both ischemic and hemorrhagic stroke. Space-occupying intracranial lesions, such as primary brain tumors or metastatic disease, rarely present acutely but can be excluded via CT scan. Intracranial hemorrhages (subdural, epidural, subarachnoid, intracerebral) mimic ischemic stroke and are differentiated via NCCT. Psychiatric conditions, including conversion disorder and malingering, are identified through meticulous neurological examination.

Hyperacute Management and Reperfusion Therapies

Revascularization of ischemic tissue within a narrow hyperacute time window is essential to salvage the penumbra and improve long-term functional recovery. Intravenous recombinant tissue plasminogen activator (rt-PA, alteplase) is an FDA-approved pharmacological therapy for acute ischemic stroke up to 3 hours after symptom onset. Intravenous rt-PA converts plasminogen to plasmin, inducing enzymatic degradation of fibrin clots.

Intravenous rt-PA is indicated for acute ischemic stroke patients presenting within 3 hours of symptom onset who meet specific eligibility criteria. The standard dosing regimen is $0.9 \text{ mg/kg}$ of body weight (maximum total dose of $90 \text{ mg}$), delivered as an initial $10\%$ bolus over 1 minute, followed by continuous intravenous infusion of the remaining $90\%$ over 60 minutes. Clinical trials conducted by the National Institute of Neurological Disorders and Stroke (NINDS) established that patients treated with IV rt-PA are at least 30% more likely to recover to independent function (no disability) at 3, 6, and 12 months compared to placebo. Symptomatic intracranial hemorrhage within 36 hours occurred in 6.5% of rt-PA treated patients versus 0.6% in placebo controls, with absolute 1-year mortality reaching 24% in the rt-PA group compared to 28% in placebo. Strict compliance with clinical inclusion and exclusion criteria is required to optimize safety.

For acute ischemic stroke caused by middle cerebral artery (MCA) occlusion within 6 hours of onset, direct intra-arterial thrombolysis provides a targeted alternative or adjunct. The PROACT-II trial evaluated intra-arterial prourokinase (Prolyse) combined with IV heparin, demonstrating arterial recanalization in 67% of treated patients versus 18% in placebo controls. Three months post-stroke, 40% of prourokinase-treated patients achieved functional independence compared to 25% of placebo controls. Symptomatic intracerebral hemorrhage occurred in 10.2% of treated patients versus 1.8% in controls. Off-label intra-arterial rt-PA (commonly dosed at $0.2 \text{ mg/kg}$, maximum $20 \text{ mg}$) is utilized in specialized centers following similar intra-arterial protocols.

Acute Supportive Care and Hemodynamic Regulation

Managing acute stroke in dedicated stroke units significantly reduces morbidity, mortality, and long-term disability. General medical supportive care requires continuous regulation of systemic physiological parameters:

• Respiration: Respiratory function must be evaluated immediately. Ventilatory drive is usually intact except after medullary or massive hemispheric infarction or hemorrhage. Airway protection from aspiration is critical; intubation and mechanical ventilation may be required in severe cases. Supplemental oxygen should be provided to maintain oxygen saturation above 95%.
• Blood Pressure Management: Cerebral blood flow to ischemic regions depends directly on cerebral perfusion pressure. Rapid blood pressure lowering can further impair cerebral blood flow and worsen ischemic injury. Elevated blood pressure often improves spontaneously during the first few days post-stroke. Antihypertensive therapy is indicated prior to and during thrombolysis with rt-PA, when infarction converts to hemorrhage, or in the presence of coexisting myocardial ischemia, aortic dissection, or hypertensive encephalopathy. Candidates for thrombolysis require modest measures (e.g., topical nitropaste or small IV labetalol boluses) to keep blood pressure below $185/110 \text{ mmHg}$. Definitive IV infusions of nicardipine, labetalol, or sodium nitroprusside are appropriate for other specific indications. After IV rt-PA, blood pressure must be maintained below $185/110 \text{ mmHg}$ for at least 24 hours.
• Fluid Volume and Hemodynamics: Careful volume replacement improves cardiac output and cerebral perfusion. Patients should receive isotonic saline to maintain euvolemia. Hypervolemic hemodilution to increase cerebral blood flow has yielded mixed results in clinical trials and is not routinely recommended.
• Temperature Control: Brain and body temperature strongly influence post-stroke outcomes. Fever or mild hyperthermia increases the odds of severe disability or death, with risk doubling for each $1^\circ\text{C}$ ($1.8^\circ\text{F}$) elevation above normal. Normothermia should be actively maintained using antipyretics or cooling blankets.
• Glycemic Regulation: Hyperglycemia correlates with poor neurological outcomes, as elevated glucose is metabolized to lactic acid, promoting tissue acidosis and cellular injury. Normalization of blood glucose is recommended, and parenteral glucose administration should be minimized.
• Preventive Prophylaxis: Deep vein thrombosis (DVT) prophylaxis should be initiated early using subcutaneous heparin ($5,000 \text{ units}$ every 12 hours) or pneumatic compression stockings when anticoagulation is contraindicated. Early intervention with physical therapy, occupational therapy, and speech therapy aids functional recovery and prevents secondary medical complications.

Intracranial Pressure and Cerebral Edema Management

Severe ischemic infarctions can trigger expanding cerebral edema that peaks 2 to 5 days post-stroke, causing focal and diffuse mass effect. Large hemispheric strokes can precipitate malignant MCA syndrome, in which edematous tissue compresses adjacent anterior and posterior cerebral arteries, producing secondary infarctions. Similarly, acute cerebellar infarction can cause basilar artery compression, fourth ventricle distortion, obstructive hydrocephalus, and brainstem ischemia. Mortality in both malignant MCA syndrome and space-occupying cerebellar infarction approaches 80% under conservative medical management.

Surgical intervention plays a critical role in selected critically ill stroke patients. In acute cerebellar stroke, suboccipital craniectomy with resection of infarcted tissue removes mass effect, prevents brainstem compression, and serves as a lifesaving intervention. Decompressive hemicraniectomy for malignant MCA syndrome provides physical space for brain expansion and is utilized to reduce mortality.

Secondary Prevention and Long-Term Pharmacotherapy

Risk Factor Modification

Reduction of modifiable cardiovascular risk factors is essential for secondary stroke prevention.

Hypertension carries the highest population-attributable risk for stroke. Blood pressure reduction lowers primary stroke risk by 25% to 47%. Treating both systolic and diastolic hypertension, including isolated systolic hypertension in elderly cohorts, markedly reduces stroke incidence. Recommended target blood pressure is below $140/90 \text{ mmHg}$. Drugs acting on the renin-angiotensin system demonstrate distinct protective benefits in primary and secondary prevention. ACE inhibitors—such as ramipril or perindopril combined with indapamide—reduce recurrent stroke risk by 25% to 30%, even in normotensive individuals. Angiotensin receptor blockers (ARBs), such as losartan, achieve a relative risk reduction in first stroke compared to beta-blockers. Thiazide diuretics (e.g., chlorthalidone) demonstrate high efficacy and safety.

Hyperlipidemia is an independent stroke risk factor. High-potency HMG-CoA reductase inhibitors (statins) significantly reduce stroke rates. The Heart Protection Study (HPS) confirmed that long-term simvastatin ($40 \text{ mg}$ daily for $> 5 \text{ years}$) reduced all strokes by 27% in high-risk individuals. Pravastatin therapy achieves a 19% to 31% relative risk reduction in stroke among patients with established coronary heart disease. Statins exert protective actions through lipid regulation as well as pleiotropic anti-inflammatory and antithrombotic effects.

Cigarette smoking increases stroke risk 2.5-fold. Smoking cessation among light smokers ($< 1 \text{ pack/day}$) reduces stroke risk to baseline within 5 years. Diabetes mellitus is a major risk factor; aggressive treatment of coexisting hypertension and dyslipidemia effectively lowers stroke risk in diabetic cohorts. Light-to-moderate alcohol intake (1 to 2 drinks daily) demonstrates a protective effect reducing stroke risk by up to 50%, whereas heavy consumption ($> 6 \text{ drinks/day}$) sharply increases stroke risk. Elevated homocysteine levels represent an independent risk factor; while high-dose vitamin $\text{B}_6$, $\text{B}_{12}$, and folic acid lower homocysteine levels, clinical trials show no direct reduction in stroke incidence. Regular physical exercise significantly reduces stroke risk by improving systemic blood pressure, lipid profiles, and glycemic control.

Antiplatelet and Antithrombotic Strategies

Antiplatelet agents are indicated for secondary prevention of non-cardioembolic ischemic stroke and TIA. Aspirin administered at doses of 160 to 325 mg daily within 48 hours of stroke onset reduces recurrent early stroke risk. For long-term prevention, daily doses of 50 to 325 mg maximize antithrombotic efficacy while minimizing gastrointestinal side effects. Aspirin reduces nonfatal stroke risk by approximately 30%.

Alternative antiplatelet regimens provide additional preventive benefits:

• Extended-Release Dipyridamole plus Aspirin: Dipyridamole inhibits platelet phosphodiesterase activity, increasing adenosine availability. The European Stroke Prevention Study-2 (ESPS-2) demonstrated that combining extended-release dipyridamole ($200 \text{ mg}$) with aspirin ($25 \text{ mg}$) twice daily achieved a 23% relative risk reduction over aspirin alone.
• Clopidogrel: Inhibits ADP-induced platelet aggregation. The CAPRIE trial showed that clopidogrel ($75 \text{ mg}$ daily) yielded a 7.3% relative risk reduction compared to aspirin. Clopidogrel has a lower risk of neutropenia than ticlopidine, though rare cases of thrombotic thrombocytopenic purpura (TTP) have been reported.
• Ticlopidine: Achieves a 21% relative risk reduction over aspirin. However, ticlopidine can cause significant neutropenia and thrombocytopenia, requiring complete blood count monitoring every 2 weeks during the first 3 months of therapy.

Oral anticoagulation with warfarin is required for secondary prevention in high-risk cardioembolic stroke sources, particularly nonvalvular atrial fibrillation (targeting an INR of 2.0 to 3.0). Oral direct thrombin inhibitors, such as ximelagatran, demonstrate efficacy and safety comparable to warfarin in atrial fibrillation without requiring routine INR monitoring.

For non-cardioembolic ischemic strokes, trials such as WARSS (Warfarin Aspirin Recurrent Stroke Study) and WASID (Warfarin versus Aspirin for Symptomatic Intracranial Disease) demonstrated that warfarin provides no superior benefit over aspirin in preventing recurrent stroke or death, while carrying higher bleeding risks. Consequently, aspirin remains the preferred agent for non-cardioembolic stroke and symptomatic intracranial arterial stenosis.

Surgical and Interventional Management

Carotid endarterectomy (CEA) dramatically reduces stroke risk in good surgical candidates with symptomatic high-grade carotid artery stenosis. In patients with symptomatic stenosis $> 70\%$, surgical intervention combined with medical therapy reduces 2-year stroke risk from 26% to 9% (a 17% absolute risk reduction). For moderate symptomatic stenosis (50% to 70%), CEA reduces 5-year stroke risk from 22% to 16%. Endarterectomy is most beneficial when performed within 2 to 4 weeks of the index cerebrovascular event. To maintain surgical benefit, perioperative complication rates must not exceed 6%.

In asymptomatic carotid stenosis $> 60\%$, the Asymptomatic Carotid Atherosclerosis Study (ACAS) showed that CEA reduced 5-year stroke risk from 11% to 5%. However, surgical risk must remain under 3% to preserve this clinical benefit. Carotid angioplasty and stenting (CAS) serves as an alternative to CEA in high-risk surgical patients, such as those with severe coexisting cardiac disease or previous carotid endarterectomy.

Special Cerebrovascular Etiologies

Arterial Dissection

Dissection of the internal carotid or vertebral arteries accounts for a significant proportion of ischemic strokes in young adults ($< 45 \text{ years}$). Dissections can occur spontaneously or secondary to blunt head and neck trauma. Connective tissue disorders—such as fibromuscular dysplasia, Marfan syndrome, and Ehlers-Danlos syndrome—represent underlying predisposing factors. Intramural hemorrhage creates vessel stenosis, occlusion, or dissecting aneurysms. Clinical features include neck pain, headache, painful partial Horner syndrome, subjective bruits, and TIA or ischemic stroke deficits. Conventional angiography displays characteristic findings, including the "string sign," tapered stenosis, dissecting aneurysms, or intimal flaps. Non-invasive diagnosis is accomplished via CTA, MRI, or MRA. Treatment centers on immediate antithrombotic therapy with heparin or aspirin until serial vascular imaging confirms recanalization or stabilization.

Inflammatory Arteriopathy

Vasculitides are conditions in which vascular wall inflammation results in cerebral ischemia. Vasculitis may be primary (isolated angiitis of the central nervous system) or secondary to systemic disorders (systemic lupus erythematosus, polyarteritis nodosa, Wegener granulomatosis, giant cell arteritis), infections (syphilis, tuberculosis, varicella-zoster virus), or illicit drugs (cocaine, amphetamines). Symptoms include headache, seizures, focal neurological deficits, and encephalopathy. Angiography characteristically reveals segmental narrowing and ectasia ("beading"). Brain biopsy provides definitive diagnosis. Immunosuppressive therapy with corticosteroids and cyclophosphamide represents the standard therapeutic approach.

Cerebral Venous Thrombosis

Cerebral venous thrombosis (CVT) is an important etiology of stroke frequently associated with pregnancy, the puerperium, hypercoagulable states, systemic infections, severe dehydration, and oral contraceptive use. Common presenting symptoms include severe progressive headache, papilledema, localized seizures, fluctuating focal weakness, and sensory deficits. Non-contrast CT can demonstrate hyperdense sinus thrombosis or venous hemorrhagic infarction, while contrast-enhanced CT may display the "empty delta sign". MRI combined with MR venography (MRV) provides high sensitivity. Acute anticoagulation with intravenous heparin or low-molecular-weight heparin is recommended even in the presence of baseline venous hemorrhage.

Intracerebral Hemorrhage

Intracerebral hemorrhage (ICH) accounts for 11% of stroke-related mortality. Prevalence is higher in African American populations. Non-contrast head CT establishes definitive diagnosis and assesses blood volume, which, along with consciousness level, serves as a primary predictor of outcome. Medical management focuses on controlling $ICP$ and titrating mean arterial pressure below $130 \text{ mmHg}$ in patients with a history of hypertension. Surgical evacuation of hematomas remains controversial; while late evacuation is ineffective, prompt surgical drainage is indicated in cerebellar hemorrhage causing brainstem compression or hydrocephalus.

Subarachnoid Hemorrhage

Spontaneous subarachnoid hemorrhage (SAH) results primarily from ruptured saccular aneurysms along the Circle of Willis, particularly involving the anterior and posterior communicating arteries. Hypertension and cigarette smoking are major modifiable risk factors. Up to 50% of patients report a premonitory "sentinel headache" days prior to rupture. Modern head CT identifies SAH in 97% of cases presenting with "the worst headache of my life". Lumbar puncture demonstrating xanthochromia is required if CT findings are negative.

Aneurysm repair via neurosurgical clipping or endovascular coiling prevents recurrent bleeding. Results from the International Subarachnoid Aneurysm Trial (ISAT) demonstrated improved 1-year disability-free survival with endovascular coiling in eligible ruptured aneurysms. Oral nimodipine ($60 \text{ mg}$ every 4 hours for 21 days) is administered to reduce vasospasm-induced cerebral ischemia. Daily transcranial Doppler examinations monitor for vasospasm; if detected post-securing, hypervolemic, hypertensive, and hemodilution ("Triple-H") therapy is initiated to maximize cerebral blood flow.

Recovery Dynamics and Neuro-Rehabilitation

Initial stroke severity serves as a strong predictor of long-term outcome, with early neuro-improvement indicating a favorable prognosis. In general, functional recovery is greatest within the first 3 months post-stroke. Because infarcted neural tissue is irreparable, recovery relies on functional reorganization within non-injured brain tissue. Functional MRI and cortical mapping studies demonstrate that recovery involves dendritic sprouting, synaptogenesis, recruitment of adjacent ipsilateral cortex, and functional reorganization within contralateral homologous pathways. Multidisciplinary physical, occupational, and speech therapy promotes these compensatory restorative mechanisms, optimizing long-term functional independence.

Conclusion

Managing cerebrovascular disorders requires hyperacute triage, emergency neuroimaging, rapid revascularization, and secondary prevention. Reperfusion strategies, including intravenous rt-PA and intra-arterial thrombolysis, rely on salvaging the ischemic penumbra within narrow therapeutic time windows. Long-term secondary stroke prevention combines antiplatelet or anticoagulant pharmacotherapy, intensive blood pressure control, statin therapy, lifestyle modification, and surgical or interventional revascularization for symptomatic carotid arterial stenosis.